176 related articles for article (PubMed ID: 19860200)
1. [Management of anemia and bone marrow hypoplasia in the treatment of myeloid leukemia].
Yokoyama H; Harigae H
Nihon Rinsho; 2009 Oct; 67(10):1974-7. PubMed ID: 19860200
[TBL] [Abstract][Full Text] [Related]
2. [Supportive therapies for myeloid leukemia including blood transfusion and growth factors].
Yao H; Ashihara E; Maekawa T
Nihon Rinsho; 2009 Oct; 67(10):1951-7. PubMed ID: 19860196
[TBL] [Abstract][Full Text] [Related]
3. Strategies for achieving transfusion independence in myelodysplastic syndromes.
Thomas ML
Eur J Oncol Nurs; 2007 Apr; 11(2):151-8. PubMed ID: 16935559
[TBL] [Abstract][Full Text] [Related]
4. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
5. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
6. Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia: results from a post hoc analysis of a randomized phase III study.
He J; Xiu L; De Porre P; Dass R; Thomas X
Leuk Lymphoma; 2015 Apr; 56(4):1033-42. PubMed ID: 25098427
[TBL] [Abstract][Full Text] [Related]
7. Acute leukemia complicating bone marrow hypoplasia in an adult with Shwachman's syndrome.
Seymour JF; Escudier SM
Leuk Lymphoma; 1993 Dec; 12(1-2):131-5. PubMed ID: 7512852
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy.
Stone R; Sekeres M; Garcia-Manero G; Lyons RM
Clin Adv Hematol Oncol; 2008 Dec; 6(12):1-15. PubMed ID: 19385003
[TBL] [Abstract][Full Text] [Related]
9. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
[TBL] [Abstract][Full Text] [Related]
10. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
Silverman LR; Demakos EP; Peterson BL; Kornblith AB; Holland JC; Odchimar-Reissig R; Stone RM; Nelson D; Powell BL; DeCastro CM; Ellerton J; Larson RA; Schiffer CA; Holland JF
J Clin Oncol; 2002 May; 20(10):2429-40. PubMed ID: 12011120
[TBL] [Abstract][Full Text] [Related]
11. Colony growth in cultures from bone marrow and peripheral blood after curative treatment for leukemia and severe aplastic anemia.
Betticher DC; Huxol H; Müller R; Speck B; Nissen C
Exp Hematol; 1993 Nov; 21(12):1517-21. PubMed ID: 8405233
[TBL] [Abstract][Full Text] [Related]
12. The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50.
Uchida T; Hagihara M; Hua J; Inoue M
Leuk Res; 2017 Feb; 53():35-38. PubMed ID: 28013105
[TBL] [Abstract][Full Text] [Related]
13. Complete remission in hypoplastic acute myeloid leukemia induced by G-CSF without chemotherapy: report on three cases.
Nimubona S; Grulois I; Bernard M; Drénou B; Godard M; Fauchet R; Lamy T
Leukemia; 2002 Sep; 16(9):1871-3. PubMed ID: 12200710
[No Abstract] [Full Text] [Related]
14. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.
Silverman LR; Holland JF; Weinberg RS; Alter BP; Davis RB; Ellison RR; Demakos EP; Cornell CJ; Carey RW; Schiffer C
Leukemia; 1993 May; 7 Suppl 1():21-9. PubMed ID: 7683352
[TBL] [Abstract][Full Text] [Related]
15. Decitabine studies in chronic and acute myelogenous leukemia.
Kantarjian HM; O'Brien SM; Estey E; Giralt S; Beran M; Rios MB; Keating M; de Vos D; Talpaz M
Leukemia; 1997 Mar; 11 Suppl 1():S35-6. PubMed ID: 9130691
[No Abstract] [Full Text] [Related]
16. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
17. Gelatinous transformation of bone marrow.
Basu S; Marwaha N; Ahluwalia M
J Assoc Physicians India; 2001 Jun; 49():674-5. PubMed ID: 11584953
[No Abstract] [Full Text] [Related]
18. [Successful treatment with azacitidine for a patient with relapsed myelodysplastic syndrome after cord blood transplantation].
Ueda S; Miyakoshi S; Chizuka A; Kojima R; Ogasawara T; Miyamoto K
Rinsho Ketsueki; 2013 Dec; 54(12):2177-81. PubMed ID: 24452149
[TBL] [Abstract][Full Text] [Related]
19. [Transfusion in palliative care in child with malignant disease].
Munzer M
Transfus Clin Biol; 2010 Dec; 17(5-6):353-6. PubMed ID: 21051262
[TBL] [Abstract][Full Text] [Related]
20. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
